Shopify reported decent Q3 results as well as an acceleration in gross merchandise volume growth but failed to beat earnings ...
Ginkgo Bioworks Stock Plummets Following Q3 Estimates Miss, Reaffirms FY2025 Outlook Below Consensus
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial ...
Zacks Investment Research on MSN
StoneCo (STNE) Upgraded to Strong Buy: Here's What You Should Know
StoneCo Ltd. (STNE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Zacks Investment Research on MSN
Fiserv Q3 Earnings Miss Estimates on Weak Margins, Revenues Fall Y/Y
Fiserv, Inc. FI delivered dismal third-quarter 2025 results as the Financial Solutions segment’s revenues declined and ...
Brookfield (BAM) delivered earnings and revenue surprises of +2.50% and +4.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Cmb.Tech NV trades at a significant discount to NAV, offering an attractive entry point for investors. Learn more about CMBT ...
SoundHound AI (SOUN) delivered earnings and revenue surprises of +25.00% and +4.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Management noted five major hyperscale customers are now engaged. In the AI and cloud infrastructure race, that’s the ...
Australia's biggest investment bank Macquarie Group recorded a 3% rise in first-half profit but missed expectations after the bank's earnings were hit by a sharp drop in commodity and markets trading ...
Genpact maintained its adjusted income from operations margin outlook at approximately 17.4% for the full year. During the quarter, the company repurchased approximately 2.0 million common shares for ...
Shares of Fortinet (NASDAQ: FTNT), a cybersecurity company, tumbled today after the company reported its third-quarter ...
Sun Pharma's strong Q2-FY25 results exceed estimates, prompting a target price revision to ₹2,000 by InCred Equities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results